Investigational drug · Phase 2
FDC fianlimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma (HNSCC).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
23
Any phase or sponsor naming "FDC fianlimab"
First trial start
2026
Apr 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FDC fianlimab", any sponsor or status.
- Phase 217
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FDC fianlimab" as an intervention, largest first.
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05608291 · 1,564 participants · Start Jan 16, 2023 · Primary completion Jan 15, 2027
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; San Francisco, California; Santa Monica, California · 211 sites in all
- Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05352672 · 1,546 participants · Start Jul 14, 2022 · Primary completion Mar 12, 2026
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; Orlando, Florida · 210 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04590326 · 612 participants (planned) · Start Dec 8, 2020 · Primary completion Nov 8, 2028
Drug: REGN5668; Cemiplimab and 3 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer and 1 more
Sites: Duarte, California; Irvine, California; Orange, California · 28 sites in all
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06246916 · 560 participants (planned) · Start Sep 9, 2024 · Primary completion Mar 22, 2027
Drug: fianlimab; cemiplimab and 1 more · For: Melanoma
Sites: Chandler, Arizona; Gilbert, Arizona; Tucson, Arizona · 113 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03005782 · 333 participants · Start Nov 7, 2016 · Primary completion Apr 2, 2024
Drug: REGN3767; cemiplimab · For: Malignancies
Sites: Encinitas, California; Fresno, California; La Jolla, California · 43 sites in all
- A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05800015 · 160 participants · Start Aug 8, 2023 · Primary completion Jan 16, 2030
Drug: fianlimab; cemiplimab and 5 more · For: Non-small Cell Lung Cancer
Sites: Tucson, Arizona; Yuma, Arizona; Cerritos, California · 76 sites in all
- A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06190951 · 151 participants · Start Sep 18, 2024 · Primary completion Nov 2, 2026
Drug: cemiplimab; Fixed Dose Combination (FDC) cemiplimab+fianlimab and 1 more · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; Newport Beach, California · 104 sites in all
- A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05785767 · 149 participants · Start Jun 30, 2023 · Primary completion Sep 28, 2027
Drug: fianlimab; cemiplimab and 1 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Tucson, Arizona; Yuma, Arizona; Redlands, California · 106 sites in all
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaPivotal-lookingRecruiting
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
NCT07234058 · 126 participants (planned) · Start Apr 2, 2026 · Primary completion May 2028
Drug: Cemiplimab; Fianlimab and 3 more · For: Pleural Mesotheliomas
Sites: Aix-en-Provence, France; Amiens, France; Angers, France · 37 sites in all
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06769698 · 120 participants (planned) · Start Apr 14, 2026 · Primary completion Jun 4, 2028
Drug: FDC fianlimab+cemiplimab; Cemiplimab and 1 more · For: Head and Neck Squamous Cell Carcinoma (HNSCC)
Sites: Los Angeles, California; Orlando, Florida; Atlanta, Georgia · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Head and Neck Squamous Cell Carcinoma (HNSCC)
- INBRX-106OrdastobartPhase 31 trial
Inhibrx Biosciences, Inc · Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
- AK129Phase 22 trials
Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
- GEN1042Phase 21 trial
Genmab · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- GTAEXS617REC-617Phase 21 trial
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)
- MT-4561Phase 21 trial
Tanabe Pharma America, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.